Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Back to Search
Print
Bookmark Trial

NCT00372567

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Detroit, Michigan, 48201, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Gastrointestinal Stromal Tumor
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with gastrointestinal stromal tumors whose disease has progressed on imatinib 400 mg daily.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Current treatment with any chemotherapy other than imatinib.


- Current treatment with any dose of imatinib other than 400 mg

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Gastrointestinal Stromal TumorPhase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
NCT02164240
  1. Boston, Massachusetts
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Gastrointestinal Stromal TumorA Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
NCT00075218
  1. Duarte, California
  2. Los Angeles, California
  3. Los Angeles, California
  4. Pasadena, California
  5. Santa Monica, California
  6. Stanford, California
  7. Washington, District of Columbia
  8. Miami, Florida
  9. Tampa, Florida
  10. Park Ridge, Illinois
  11. Boston, Massachusetts
  12. Detroit, Michigan
  13. Minneapolis, Minnesota
  14. St. Louis, Missouri
  15. New York, New York
  16. New York, New York
  17. New York, New York
  18. Durham, North Carolina
  19. Cleveland, Ohio
  20. Columbus, Ohio
  21. Columubs, Ohio
  22. Portland, Oregon
  23. Philadelphia, Pennsylvania
  24. Nashville, Tennessee
  25. Seattle, Washington
  26. Seattle, Washington
  27. Madison, Wisconsin
  28. Garran, Australian Capital Territory
  29. Camperdown, New South Wales
  30. Randwick, New South Wales
  31. Auchenflower, Queensland
  32. Ashford, South Australia
  33. Bedford Park, South Australia
  34. East Melbourne, Victoria
  35. Leuven,
  36. Toronto, Ontario
  37. Montreal, Quebec
  38. Lyon,
  39. Marseille,
  40. VILLEJUIF Cedex,
  41. Aviano, PN
  42. Candiolo, Torino
  43. Bologna,
  44. Genova,
  45. Milano,
  46. Milano,
  47. Milano,
  48. Torino,
  49. Groningen, Gr
  50. Rotterdam, ZH
  51. Singapore,
  52. Singapore,
  53. Singapore,
  54. L'Hospitalet del Llobregat, Barcelona
  55. Barcelona,
  56. Madrid,
  57. Lausanne,
  58. Sutton, Surrey
  59. Leeds,
  60. London,
  61. Newcastle-Upon-Tyne,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Gastrointestinal Stromal TumorSafety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
NCT00372567
  1. Detroit, Michigan
  2. Farmington Hills, Michigan
  3. Creve Coeur, Missouri
  4. St. Louis, Missouri
  5. St. Peters, Missouri
  6. Philadelphia, Pennsylvania
  7. Goettingen,
  8. Hamburg,
  9. Lai Chi Kok, Kowloon
  10. Tuen Mun, New Territories
  11. Hong Kong,
  12. Bologna,
  13. Milano,
  14. San Giovanni Rotondo,
  15. Seoul,
  16. Seoul,
  17. Seoul,
  18. Barcelona,
  19. Valencia,
  20. Glasgow,
  21. Leeds,
  22. London,
  23. London,
  24. London,
  25. Manchester,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Official Title  ICMJE A Phase IIIB, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 Mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 Mg Daily Of Imatinib
Brief Summary A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or imatinib 800 mg daily. This study will find out the benefits and potential side effects of taking sunitinib or imatinib for approximately one year.
Detailed Description The study prematurely discontinued on July 27, 2009 due to poor recruitment and operational futility as a result of changes in clinical practice. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Gastrointestinal Stromal Tumor
Intervention  ICMJE
  • Drug: sunitinib malate
    37.5 mg daily
    Other Name: Sutent
  • Drug: imatinib mesylate
    800mg daily
Study Arms  ICMJE
  • Experimental: A
    Intervention: Drug: sunitinib malate
  • Active Comparator: B
    Intervention: Drug: imatinib mesylate
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: March 5, 2010)		69
Original Enrollment  ICMJE
 (submitted: September 5, 2006)		212
Actual Study Completion Date  ICMJE November 2009
Actual Primary Completion Date November 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with gastrointestinal stromal tumors whose disease has progressed on imatinib 400 mg daily.

Exclusion Criteria:

  • Current treatment with any chemotherapy other than imatinib.
  • Current treatment with any dose of imatinib other than 400 mg
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany,   Hong Kong,   Italy,   Korea, Republic of,   Spain,   United Kingdom,   United States
Removed Location Countries France
 
Administrative Information
NCT Number  ICMJE NCT00372567
Other Study ID Numbers  ICMJE A6181112
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer Inc
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP